AN UPHILL CLIMB

It’s been a long winter –and an expensive one for a lot of us. The European energy crisis remains a pressing concern, for both the industrial sector and on a personal scale.

Disruption to access of raw materials from Covid-19 lockdowns in China, coupled with a surge in energy costs following Russia’s invasion of Ukraine, has left pharma companies sounding the alarm on the rising manufacturing costs.

Being that pharma is an energy-intensive sector, from containment labs through to industrial manufacturing sites, cutting down costs would not prove easy without impacting product quality and capacity. Both of which are non-negotiable when it comes to pharma.

On top of this, the rising costs are widespread across Europe. Combine this with the looser regulatory requirements, many pharma companies have been indirectly swayed to move their production of active pharmaceutical ingredients (APIs) to less energy